PL365697A1 - Zastosowanie inhibitorów IL-18 do leczenia i/lub zapobiegania miażdżycy tętnic - Google Patents

Zastosowanie inhibitorów IL-18 do leczenia i/lub zapobiegania miażdżycy tętnic

Info

Publication number
PL365697A1
PL365697A1 PL01365697A PL36569701A PL365697A1 PL 365697 A1 PL365697 A1 PL 365697A1 PL 01365697 A PL01365697 A PL 01365697A PL 36569701 A PL36569701 A PL 36569701A PL 365697 A1 PL365697 A1 PL 365697A1
Authority
PL
Poland
Prior art keywords
atherosclerosis
inhibitors
prevention
treatment
Prior art date
Application number
PL01365697A
Other languages
English (en)
Other versions
PL209371B1 (pl
Inventor
Yolande Chvatchko
Alain Tedgui
Ziad Mallat
Original Assignee
Applied Research Systems Ars Holding N.V.
Institut National De La Sante Et De La Recherche Medicale (Inserm)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N.V., Institut National De La Sante Et De La Recherche Medicale (Inserm) filed Critical Applied Research Systems Ars Holding N.V.
Publication of PL365697A1 publication Critical patent/PL365697A1/pl
Publication of PL209371B1 publication Critical patent/PL209371B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
PL365697A 2000-05-05 2001-04-30 Zastosowanie inhibitora IL-18, zastosowanie wektora ekspresyjnego zawierającego sekwencję kodującą inhibitor IL-18, zastosowanie genetycznie modyfikowanych komórek wytwarzających inhibitor IL-18 oraz zastosowanie IL-18 PL209371B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00109606 2000-05-05
PCT/EP2001/004843 WO2001085201A2 (en) 2000-05-05 2001-04-30 Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis

Publications (2)

Publication Number Publication Date
PL365697A1 true PL365697A1 (pl) 2005-01-10
PL209371B1 PL209371B1 (pl) 2011-08-31

Family

ID=8168631

Family Applications (1)

Application Number Title Priority Date Filing Date
PL365697A PL209371B1 (pl) 2000-05-05 2001-04-30 Zastosowanie inhibitora IL-18, zastosowanie wektora ekspresyjnego zawierającego sekwencję kodującą inhibitor IL-18, zastosowanie genetycznie modyfikowanych komórek wytwarzających inhibitor IL-18 oraz zastosowanie IL-18

Country Status (32)

Country Link
US (1) US20040076628A1 (pl)
EP (1) EP1278540B1 (pl)
JP (1) JP5122053B2 (pl)
KR (2) KR100798545B1 (pl)
CN (2) CN1841066B (pl)
AR (1) AR035640A1 (pl)
AT (1) ATE395075T1 (pl)
AU (2) AU2001267390B2 (pl)
BG (1) BG65881B1 (pl)
BR (1) BRPI0110506B8 (pl)
CA (1) CA2407895C (pl)
CY (1) CY1110385T1 (pl)
CZ (1) CZ300792B6 (pl)
DE (1) DE60134009D1 (pl)
DK (1) DK1278540T3 (pl)
EA (2) EA007014B1 (pl)
EE (1) EE05056B1 (pl)
ES (1) ES2305082T3 (pl)
HR (1) HRP20020828A2 (pl)
HU (1) HU229375B1 (pl)
IL (2) IL152567A0 (pl)
ME (1) ME00554B (pl)
MX (1) MXPA02010895A (pl)
NO (1) NO329821B1 (pl)
PL (1) PL209371B1 (pl)
PT (1) PT1278540E (pl)
RS (1) RS50926B (pl)
SI (1) SI1278540T1 (pl)
SK (1) SK287761B6 (pl)
UA (2) UA78492C2 (pl)
WO (1) WO2001085201A2 (pl)
ZA (1) ZA200208228B (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK12942002A3 (sk) * 2000-02-10 2003-05-02 Abbott Laboratories Protilátky viažuce ľudský interleukín-18, spôsoby ich výroby a použitia
IL157024A0 (en) * 2001-01-29 2004-02-08 Applied Research Systems Il-18 inhibitors in heart disease
US7655616B2 (en) * 2001-05-25 2010-02-02 Ares Trading S.A. Use of IL-18 inhibitors for treating head injuries
US6797727B2 (en) 2001-07-16 2004-09-28 Transition Therapeutics Inc. Use of rhein or diacerhein compounds for the treatment or prevention of vascular diseases
GB0210212D0 (en) * 2002-05-03 2002-06-12 Univ Southampton Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
US9592267B2 (en) * 2002-03-22 2017-03-14 Merck Serono Sa Use of IL-18BP for treatment of peripheral vascular diseases
ATE399872T1 (de) * 2003-03-11 2008-07-15 Serono Lab Expressionvektoren, die den promotor des ie2-gens des maus cytomegalovirus enthalten
AU2004238524B2 (en) 2003-05-13 2011-06-23 Merck Serono Sa Active variants of the IL-18 binding protein and medical uses thereof
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
ES2356364T3 (es) * 2004-04-15 2011-04-07 Athera Biotechnologies Ab Anexina v para prevenir la ruptura de la placa.
CN101219208B (zh) * 2005-01-04 2010-08-11 健能隆医药技术（上海）有限公司 白介素-22的医药用途
CA2609060C (en) 2005-06-03 2014-07-15 Urs Weber Production of recombinant il-18 binding protein
PT1891088E (pt) 2005-06-10 2011-12-19 Ares Trading Sa Processo para a purificação da proteína de ligação il-18
KR101603001B1 (ko) 2010-08-25 2016-03-11 에프. 호프만-라 로슈 아게 Il-18r1에 대한 항체 및 그의 용도
US9376489B2 (en) 2012-09-07 2016-06-28 Novartis Ag IL-18 binding molecules
MD707Z (ro) * 2013-01-18 2014-07-31 Институт Зоологии Академии Наук Молдовы Metodă de identificare a secvenţelor polimorfe 4a/4b ale genei sintetazei endoteliale a oxidului nitric
WO2015032932A1 (en) 2013-09-05 2015-03-12 Ab2 Bio Sa Il-18 binding protein (il-18bp) in inflammatory diseases
CN107660150B (zh) 2015-03-05 2023-10-24 Ab2生物股份有限公司 Il-18结合蛋白(il-18bp)和抗体在炎性疾病中
TW202233675A (zh) 2020-10-29 2022-09-01 瑞士商諾華公司 Ｉｌ－１８拮抗劑用於治療和／或預防異位性皮炎或相關病症之用途
CN112972655A (zh) * 2021-04-16 2021-06-18 武汉大学 白细胞介素12在制备预防、缓解和/或治疗主动脉瘤药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) * 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
US5877197A (en) * 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
EP0987552A3 (en) * 1998-08-31 2000-06-07 Pfizer Products Inc. Diarylsulfonylurea binding proteins
CA2340579A1 (en) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein

Also Published As

Publication number Publication date
SK287761B6 (en) 2011-09-05
HUP0301991A2 (hu) 2003-09-29
SI1278540T1 (sl) 2008-10-31
RS50926B (sr) 2010-08-31
SK15562002A3 (sk) 2003-05-02
EP1278540B1 (en) 2008-05-14
ME00554B (me) 2012-03-20
CN1841066B (zh) 2012-08-29
MEP64008A (en) 2011-12-20
ZA200208228B (en) 2005-07-27
KR20030016254A (ko) 2003-02-26
DK1278540T3 (da) 2008-07-21
EA005410B1 (ru) 2005-02-24
CZ300792B6 (cs) 2009-08-12
BRPI0110506B1 (pt) 2015-05-19
KR20070073989A (ko) 2007-07-10
PL209371B1 (pl) 2011-08-31
NO329821B1 (no) 2010-12-27
DE60134009D1 (de) 2008-06-26
WO2001085201A3 (en) 2002-05-10
US20040076628A1 (en) 2004-04-22
HK1055681A1 (en) 2004-01-21
YU82602A (sh) 2006-01-16
IL152567A (en) 2010-12-30
KR100798545B1 (ko) 2008-01-28
HK1094909A1 (en) 2007-04-13
EE05056B1 (et) 2008-08-15
AU2001267390B2 (en) 2005-09-22
UA87658C2 (uk) 2009-08-10
AU6739001A (en) 2001-11-20
PT1278540E (pt) 2008-07-03
HRP20020828A2 (en) 2004-12-31
BRPI0110506B8 (pt) 2021-05-25
HUP0301991A3 (en) 2006-11-28
CZ20023644A3 (cs) 2003-03-12
WO2001085201A2 (en) 2001-11-15
UA78492C2 (en) 2007-04-10
CA2407895A1 (en) 2001-11-15
NO20025307L (no) 2002-12-18
BG65881B1 (bg) 2010-04-30
EP1278540A2 (en) 2003-01-29
IL152567A0 (en) 2003-05-29
EA200401183A1 (ru) 2004-12-30
AR035640A1 (es) 2004-06-23
JP5122053B2 (ja) 2013-01-16
NO20025307D0 (no) 2002-11-05
BG107218A (bg) 2003-06-30
CA2407895C (en) 2012-12-18
MXPA02010895A (es) 2003-03-27
CN1250286C (zh) 2006-04-12
JP2003532685A (ja) 2003-11-05
EE200200620A (et) 2004-06-15
CN1434722A (zh) 2003-08-06
EA007014B1 (ru) 2006-06-30
BR0110506A (pt) 2003-04-01
ES2305082T3 (es) 2008-11-01
HU229375B1 (en) 2013-11-28
CN1841066A (zh) 2006-10-04
ATE395075T1 (de) 2008-05-15
EA200201175A1 (ru) 2003-04-24
CY1110385T1 (el) 2015-04-29

Similar Documents

Publication Publication Date Title
AU6739001A (en) Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
AU8870701A (en) Materials and methods for the treatment or prevention of obesity
PL364995A1 (pl) Sposób leczenia lub zapobiegania infekcjom wywołanym przez Flavivirus przy użyciu analogów nukleozydów
SI1251848T1 (en) Gyrase inhibitors and uses thereof
PL357713A1 (pl) Inhibitory kaspaz i ich zastosowania
GB0025782D0 (en) Use of inhibitors
AU5714601A (en) Methods for prevention and treatment of gastrointestinal disorders
PL356066A1 (pl) Inhibitory kaspazy i ich zastosowanie
IL146000A0 (en) Ace-2 inhibiting compounds and methods of use thereof
EP1337255A4 (en) USE OF P38 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY COUGH
HUP0300061A3 (en) Use of il-18 inhibitors
AU1334602A (en) Osteopontin-coated surfaces and methods of use
AU2002364171A8 (en) Materials and methods for the treatment or prevention of obesity
IL131047A0 (en) Use of il-18 inhibitors
HUP0303306A3 (en) Use of il-18 inhibitors for the treatment and/or prevention of heart disease
PL361733A1 (pl) Sulfamidotienopirymidyny
HUP0302738A3 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
IL154927A0 (en) Combination of statins and sorbitol dehydrogenase inhibitors
AU2002222125A1 (en) Prevention and treatment of tachyphylactic response
AU1212002A (en) Use of lipase inhibitors
EP1305017A4 (en) METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF SYNDROME X
IL143903A0 (en) Use of phanquinone for the treatment or prevention of memory impairment
IL165870A0 (en) Use of chymase inhibitors for the prevention and/or
GB0119460D0 (en) The use of inhibitors of the renin-angiotensin system
GB0015035D0 (en) Prevention of adhesions